TABLE 2.
Analysis of Sarcomas Expressing MUC16, Specifically Epithelioid Sarcoma and Extracranial Malignant Rhabdoid Tumors, by Measuring Histochemical (H) Scores in Matched Primary Tumor and Metastatic Samples, Where Available
| Tumor Sample, Type, and Age at Diagnosis | Primary Tumor H-Score |
Metastatic Site H-Score |
|---|---|---|
| ES proximal type, 16 years | 110 | — |
| ES proximal type, 4 years | 0 | — |
| ES distal type, 12 years | 300 | — |
| ES distal type, 8 years | 300 | — |
| ES proximal type, 14 years | 0 | 0 |
| ES distal type, 12 yearsa | 300 | 300 |
| ES distal type, 8 years | 300 | — |
| ES type NS, 22 years | 85 (sample NS)b | |
| MRT kidney, 2.5 years | 0 | 0 |
| MRT extrarenal, 6 days | 300 | — |
| MRT extrarenal, 8 months | 170 | 300 |
| MRT kidney, 2 years | 0 | — |
NOTE. These H scores semiquantitatively assess the degree of MUC16 expression, ranging from 0, indicating negative staining, to 300, indicating intense, widespread positive MUC16 staining.
Abbreviations: ES, epithelioid sarcoma; H-score, histochemical score; MRT, malignant rhabdoid tumor; MUC16, mucin 16; NS, sample origin not specified.
a
Patient described in case report.
b
NS: Type of epithelioid sarcoma and sample origin not specified.